The plasma fractionation market focuses on processing human plasma to extract vital therapeutic proteins, such as immunoglobulins, albumin, coagulation factors, and enzyme replacements. These derivatives are essential for treating immune deficiencies, bleeding disorders, and various chronic and acute conditions. Growth in this market is driven by increasing global demand for plasma-derived therapies, advances in fractionation technology, and the expansion of plasma collection infrastructure. As healthcare access improves worldwide and rare disease diagnosis rises, the plasma fractionation industry is set to continue growing steadily in the years ahead.
According to Fortune Business Insights, the global plasma fractionation market was valued at USD 37.31 billion in 2024 and is projected to grow from USD 40.27 billion in 2025 to USD 72.45 billion by 2032, exhibiting a CAGR of 8.8% during the forecast period. In 2024, North America dominated the plasma fractionation market with a market share of 56.18%.
Top Companies in the Market
- CSL Behring (CSL) (U.S.)
- Grifols, S.A. (Spain)
- Takeda Pharmaceutical Company Limited (Japan)
- Kedrion S.p.A (Italy)
- Octapharma (Switzerland)
- ADMA Biologics, Inc. (U.S.)
- Sartorius AG (Germany)
- LFB (France)
Key Industry Development
In July 2024, Kedrion S.p.A. announced a long-term commercialization and distribution agreement for Yimmugo—a key immunoglobulin therapy—in the U.S. through collaboration with Biotest AG. This strategic move underscores Kedrion's focus on expanding its product reach and bolstering its U.S. footprint.
Market Drivers & Restraints
Key Drivers
- Rising Chronic & Immunodeficiency Disorders: Increased prevalence of autoimmune, bleeding, and immunodeficiency disorders is fueling demand for plasma-derived therapies.
- Technological Advancements: Innovations in fractionation processes and collection technologies—such as new plasmapheresis systems—are improving yield and donor safety.
- Expanding Donor Networks: Industry leaders like Grifols, CSL, and Takeda are rapidly scaling plasma collection facilities. Notably, Takeda’s BioLife Plasma Services opened its 200th center in 2023.
Key Restraints
- Stringent Regulatory Landscape: High safety standards and lengthy approval procedures for plasma therapies may slow product launch timelines.
- Supply Vulnerability: Ensuring sufficient supply of high-quality plasma is challenging, especially during pandemics or public health crises.
Market Report Coverage
The Fortune Business Insights report analyzes key segments including product types (immunoglobulins, albumin, coagulation factors, protease inhibitors), applications (immunology, hematology, critical care), end-users, and regional performance. It also includes market forecasts, COVID-19 impact, competitive dynamics, and strategic initiatives.
Competitive Landscape
The plasma fractionation market remains highly consolidated, dominated by major players like CSL Behring, Grifols, Takeda, Octapharma, and Kedrion S.p.A. These companies are differentiating themselves through:
- Expanding plasma collection networks globally (e.g., Kedrion’s recent center acquisitions in Czech Republic).
- Gaining regulatory approvals and pipeline rollouts, such as Keizo’s licensing in the U.S..
- R&D investments targeting new indications (e.g., neurological and autoimmune diseases).
Market Segmentation
By Product
- Immunoglobulins (IVIG/SCIG): The largest and fastest-growing segment, widely used to treat immune disorders.
- Albumin: Used in critical care and surgical applications.
- Coagulation Factors: Includes Factor VIII/IX for hemophilia and von Willebrand factor (e.g., Octapharma’s wilate).
- Protease Inhibitors: An emerging segment projected to gain traction.
- Others: Includes niche proteins and specialty formulations.
By Application
- Immunology & Neurology
- Hematology
- Critical Care
- Pulmonology
- Others: Includes metabolic and rare disease applications.
By End-User
- Hospitals & Clinics
- Clinical Research Laboratories
- Others: Home healthcare, specialty centers
Regional Insights
North America
With a commanding 56.18% market share in 2024 (USD 20.96 billion), North America is the world leader thanks to advanced infrastructure, robust plasma collection, and a dense network of treatment centers.
Europe
Europe ranks second in market share, buoyed by rising immunodeficiency disorders, enhanced plasma networks, and strategic industry activities.
Asia Pacific
While currently smaller, Asia Pacific is fastest-growing due to rising healthcare investment and expanding biotechnology infrastructure.
Latin America & Middle East, Africa
Steady growth driven by expanding healthcare systems, rising awareness, and new plasma partnerships—evident in contracts like GC Biopharma’s IVIG agreement in Brazil.
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614
Future Market Scope
The outlook for the plasma fractionation market remains positive:
- Innovative Therapies: New treatment targets in autoimmune, neurology, and rare diseases will broaden therapeutic applications.
- Network Expansion: Ongoing global launches of plasma collection centers by Takeda, Grifols, Kedrion, and Octapharma will address supply.
- Technological Advancement: New collection systems and fractionation technologies will enhance efficiency.
- COVID-19 Impacts: The pandemic underscored plasma thermal therapy potential, prompting investment and donor growth.
Conclusion
The plasma fractionation market is on a strong growth trajectory, projected to nearly double in value by 2032. Surging demand for plasma-derived therapies, expanded donor networks, and continued innovation—backed by key industry alliances and regulatory approvals—underscore a promising future. Leading players are well-positioned to capitalize on these trends, ensuring improved accessibility and therapeutic breakthroughs for patients worldwide.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
Our reports are a blend of quantitative and qualitative analysis, aimed at helping businesses achieve sustainable growth. Our experienced analysts and consultants use leading research methodologies to provide comprehensive market assessments enriched with relevant data.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Comments
0 comment